Duloxetine Capsule, Delayed Release
Product Images NDC 82009-173

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 82009-173). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg (Duloxetine 20mg)

Label for Duloxetine Delayed-Release Capsules 20 mg, containing 1000 capsules. The label shows the drug name, dosage strength, and NDC number 82009-170-10. It includes handling instructions, storage conditions, and manufacturing details by Ajanta Pharma Limited for Quallent Pharmaceuticals Health LLC. The label also features a barcode and a designated unvarnished OPZ area for overprint details.*

FDA Label Image

30mg (Duloxetine 30mg)

Label for Duloxetine delayed-release capsules 30 mg by Quallent Pharmaceuticals Health LLC. The label states 1000 capsules per container with NDC 82009-171-10. It includes storage instructions, manufacturing details by Ajanta Pharma Limited in India, and a barcode. The design features the Quallent Pharmaceuticals logo and a purple 30 mg strength indicator.*

FDA Label Image

40mg (Duloxetine 40mg)

Packaging label for Duloxetine Delayed-Release Capsules 40 mg by Quallent Pharmaceuticals Health LLC. The label states a container size of 30 capsules and includes dosage strength, NDC 82009-172-30, manufacturer information (Ajanta Pharma Limited, India), storage instructions, and a barcode. There is also an example area for overprint details with a QR code placeholder and space for batch and expiration info.*

FDA Label Image

60mg (Duloxetine 60mg)

Label for Duloxetine Delayed-Release Capsules 60 mg by Quallent Pharmaceuticals Health LLC. The label indicates a package size of 1000 capsules with NDC 82009-173-10. It includes usage instructions, storage conditions, manufacturer details (Ajanta Pharma Limited, India), and a barcode.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A line graph depicting the proportion of patients with relapse over time in days from randomization. The graph compares two treatment groups: placebo and Duloxetine. The y-axis represents the proportion of patients with relapse ranging from 0 to 1. The x-axis shows time from randomization to relapse in days, ranging from 0 to 250. The graph shows a higher proportion of relapse in the placebo group compared to the Duloxetine group over the observed period.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The y-axis represents percentage of patients improved (0-100%), and the x-axis shows percent improvement in pain (0-100%). Duloxetine shows a higher percentage of patient improvement across most pain improvement intervals compared to placebo.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier curve comparing the proportion of patients with relapse over time (days) from randomization for Duloxetine versus placebo. The graph shows Duloxetine having a lower relapse proportion compared to placebo across approximately 250 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine. It compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The x-axis shows percent improvement in pain, and the y-axis shows the percentage of patients improved.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. The graph compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups, illustrating higher patient improvement percentages with Duloxetine doses compared to placebo as pain improvement increases.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph displaying the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo groups, showing patient response in pain improvement over a range of baseline pain reduction percentages.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at doses of 20 mg, 60 mg, and 120 mg once daily, compared to placebo. The graph illustrates higher patient improvement percentages with Duloxetine doses relative to placebo across the range of pain improvement percentages.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline, comparing Duloxetine 60 mg once daily (marked with X) and placebo (marked with dots). The graph illustrates a higher percentage of patients reporting pain improvement with Duloxetine across various improvement percentages.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline. It shows two groups: placebo and Duloxetine 60/120 mg once daily, with Duloxetine consistently showing a higher percentage of patients improved across various pain improvement thresholds from greater than 0% to 100%.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved based on percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain, ranging from >0 to 100, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Two lines represent the placebo group and the Duloxetine 60 mg group, illustrating patient response across different pain improvement thresholds.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of duloxetine as a hydrochloride salt, depicting the molecular framework including a thiophene ring, a chiral center, and a naphthalene group.*

FDA Label Image

Logo (Quallent)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.